STAT1 and uterine cervix carcinoma in situ: SOCS 3 was expressed in 95% of the samples evaluated in the Invasive group; approximately 60% in the CIN III and CIN II groups, and approximately 55% in the CIN I. STAT1 was expressed in approximately 90% of the samples in the Invasive group, ~50% in CIN III, ~80% in CIN II, and ~70% in CIN I. And IRF9 was expressed in ~45% of the samples from the Invasive group and ~20% in the other grypos (CIN III, CIN II, and CIN I) had a higher percentage of patients who expressed all transcription factors (Figure 4).